AYTU · Aytu Biopharma, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.41M | $15.16M | $13.89M | $16.22M | $18.45M | $16.57M | $22.93M | $17.99M | $22.10M | $26.28M |
| Cost of Revenue | $4.81M | $5.54M | $4.70M | $5.43M | $5.65M | $4.59M | $8.99M | $6.30M | $9.62M | $8.99M |
| Gross Profit | $7.60M | $9.62M | $9.19M | $10.79M | $12.81M | $11.98M | $16.20M | $11.69M | $14.78M | $17.29M |
| R&D | $0 | $0 | $0 | $522.0K | $162.0K | $426.0K | $524.0K | $619.0K | $604.0K | $1.71M |
| SG&A | $4.97M | $5.07M | $4.92M | $4.45M | $4.11M | $5.13M | $5.44M | $5.44M | $6.96M | $8.02M |
| Total Operating Expenses | $11.66M | $11.59M | $10.69M | $12.48M | $10.38M | $12.91M | $13.84M | $14.16M | $16.29M | $24.09M |
| D&A | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | - | $1.90M | $1.83M | $2.23M | $400.0K |
| Operating Income | ($4.06M) | ($1.97M) | ($1.50M) | ($1.70M) | $2.42M | ($930.0K) | $2.36M | ($2.46M) | ($1.50M) | ($6.79M) |
| Interest Expense | $436.0K | $560.0K | $516.0K | $1.08M | $1.26M | $994.0K | - | - | - | $700.0K |
| Income Tax | $10.0K | $0 | $0 | ($283.0K) | ($122.0K) | $405.0K | $828.0K | $245.0K | - | - |
| Net Income | ($5.62M) | ($10.58M) | $1.97M | $788.0K | $3.99M | $1.47M | ($220.0K) | ($2.89M) | ($8.12M) | ($6.69M) |
| EPS - Basic | ($0.53) | ($1.05) | $0.21 | $0.13 | $0.65 | $0.24 | ($0.04) | ($0.52) | ($1.48) | ($2.15) |
| EPS - Diluted | ($0.53) | ($1.05) | ($0.08) | ($0.26) | ($0.52) | ($0.15) | - | - | ($1.48) | ($2.15) |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $26.71M | $30.02M | $32.63M | $30.95M | $18.17M | $20.11M | $20.01M | $19.76M | $19.96M | $22.98M |
| Accounts Receivable | $24.49M | $30.92M | $33.23M | $31.16M | $35.83M | $23.16M | $23.62M | $29.93M | $29.88M | $28.94M |
| Inventory | $7.46M | $8.66M | $10.10M | $11.43M | $11.06M | $11.74M | $12.63M | $13.19M | $12.97M | $11.99M |
| Accounts Payable | $13.21M | $14.26M | $12.34M | $10.60M | $12.04M | $13.51M | $10.44M | $10.47M | - | - |
| Current Assets | $67.33M | $76.24M | $81.11M | $79.18M | $72.51M | - | $71.37M | $71.13M | $70.60M | $72.83M |
| Total Assets | $111.69M | $122.00M | $124.99M | $124.18M | $124.20M | $115.83M | $118.09M | $128.86M | $132.89M | $136.46M |
| Current Liabilities | $59.97M | $65.56M | $65.99M | $63.06M | $70.71M | $61.25M | $62.23M | $83.69M | $65.46M | $69.02M |
| Long-term Debt | $9.55M | $10.00M | $10.45M | $10.89M | $9.54M | $10.43M | $10.88M | $0 | $15.00M | $15.00M |
| Total Liabilities | - | - | - | - | - | - | - | - | $100.72M | $97.11M |
| Stockholders' Equity | $35.14M | $14.20M | $23.17M | $18.97M | $34.90M | $29.83M | $27.72M | $30.78M | $32.17M | $39.36M |
| Retained Earnings | ($347.77M) | ($342.15M) | ($331.57M) | ($333.54M) | ($313.72M) | ($318.50M) | ($319.97M) | ($315.36M) | ($312.25M) | ($304.13M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($618.0K) | - | - | - | - | - | ($211.0K) | - |
| Investing Cash Flow | - | - | $381.0K | - | - | - | - | - | ($76.0K) | - |
| Financing Cash Flow | - | - | $911.0K | - | - | - | - | - | ($2.73M) | - |
| CapEx | - | - | $136.0K | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | ($754.0K) | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 61.2% | 63.5% | 66.1% | 66.5% | 69.4% | 72.3% | 70.7% | 65.0% | 66.9% | 65.8% |
| Operating margin | -32.7% | -13.0% | -10.8% | -10.4% | 13.1% | -5.6% | 10.3% | -13.7% | -6.8% | -25.8% |
| EBITDA margin | -31.9% | -12.3% | -10.1% | -9.8% | 13.7% | - | 18.6% | -3.5% | 3.3% | -24.3% |
| Net margin | -45.3% | -69.8% | 14.1% | 4.9% | 21.6% | 8.9% | -1.0% | -16.0% | -36.7% | -25.5% |
| Free cash flow margin | - | - | -5.4% | - | - | - | - | - | - | - |
| FCF / Net income | - | - | -0.38 | - | - | - | - | - | - | - |
| R&D / Revenue | 0.0% | 0.0% | 0.0% | 3.2% | 0.9% | 2.6% | 2.3% | 3.4% | 2.7% | 6.5% |
| SG&A / Revenue | 40.1% | 33.4% | 35.5% | 27.4% | 22.3% | 30.9% | 23.7% | 30.2% | 31.5% | 30.5% |
| Effective tax rate | - | - | 0.0% | -56.0% | -3.2% | 21.6% | 136.2% | - | - | - |
| Return on assets | -5.0% | -8.7% | 1.6% | 0.6% | 3.2% | 1.3% | -0.2% | -2.2% | -6.1% | -4.9% |
| Return on equity | -16.0% | -74.5% | 8.5% | 4.2% | 11.4% | 4.9% | -0.8% | -9.4% | -25.2% | -17.0% |
| Return on invested capital | -7.2% | -6.4% | -4.5% | -5.7% | 5.4% | -1.8% | 3.1% | -6.3% | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.12 | 1.16 | 1.23 | 1.26 | 1.03 | - | 1.15 | 0.85 | 1.08 | 1.06 |
| Quick ratio | 1.00 | 1.03 | 1.08 | 1.07 | 0.87 | - | 0.94 | 0.69 | 0.88 | 0.88 |
| Cash ratio | 0.45 | 0.46 | 0.49 | 0.49 | 0.26 | 0.33 | 0.32 | 0.24 | 0.30 | 0.33 |
| Leverage | ||||||||||
| Debt / Equity | 0.27 | 0.70 | 0.45 | 0.57 | 0.27 | 0.35 | 0.39 | 0.00 | 0.47 | 0.38 |
| Debt / Assets | 0.09 | 0.08 | 0.08 | 0.09 | 0.08 | 0.09 | 0.09 | 0.00 | 0.11 | 0.11 |
| Debt / EBITDA | - | - | - | - | 3.78 | - | 2.55 | - | 20.66 | - |
| Interest coverage | -9.3x | -3.5x | -2.9x | -1.6x | 1.9x | -0.9x | - | - | - | -9.7x |
| Equity multiplier | 3.18 | 8.59 | 5.39 | 6.55 | 3.56 | 3.88 | 4.26 | 4.19 | 4.13 | 3.47 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | 0.76 | 0.71 |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | 0.12 | 0.11 | 0.13 | 0.15 | 0.14 | 0.19 | 0.14 | 0.17 | 0.19 |
| Inventory turnover | 0.65 | 0.64 | 0.47 | 0.48 | 0.51 | 0.39 | 0.71 | 0.48 | 0.74 | 0.75 |
| Days sales outstanding | 720d | 744d | 873d | 701d | 709d | 510d | 376d | 607d | 494d | 402d |
| Days inventory outstanding | 566d | 570d | 784d | 768d | 715d | 934d | 513d | 764d | 492d | 487d |
| Days payable outstanding | 1002d | 939d | 958d | 712d | 778d | 1075d | 424d | 607d | - | - |
| Cash conversion cycle | 284d | 375d | 699d | 757d | 645d | 369d | 465d | 765d | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.8x | 1.8x | 1.6x | 0.6x | 0.2x | 0.7x | - | - | 0.5x | 0.1x |
| P / S | 2.3x | 1.7x | 2.6x | 0.7x | 0.4x | 1.3x | - | - | 0.7x | 0.2x |
| EV / EBITDA | - | - | - | - | -0.8x | - | - | - | 13.6x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -32.7% | -6.5% | -16.2% | -29.3% | 2.6% | -25.0% | -12.7% | -20.9% | -20.1% | 13.6% |
| Revenue CAGR (3y) | -18.3% | -16.7% | -20.5% | -11.1% | -8.6% | -8.9% | 14.8% | 10.1% | 17.8% | 102.3% |
| Revenue CAGR (5y) | -1.6% | 0.0% | 0.5% | 38.6% | 17.7% | 63.0% | 66.4% | 49.9% | 72.9% | 90.4% |
| Gross profit growth (YoY) | -40.7% | -10.8% | -23.4% | -33.4% | 9.5% | -18.9% | -6.3% | -8.2% | -18.0% | 94.4% |
| Operating income growth (YoY) | - | -16.2% | -61.7% | - | - | 38.2% | - | 71.2% | 9.0% | 39.9% |
| Net income growth (YoY) | - | - | 33.3% | - | - | - | 96.7% | 59.9% | -181.8% | 42.0% |
| EPS growth (YoY) | -1.9% | -303.8% | 46.7% | - | - | 89.9% | - | - | -2366.7% | -388.6% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 0.7% | -25.1% | -22.3% | -31.6% | 13.4% | -7.3% | -29.6% | -24.8% | -40.3% | -14.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-06-30.
Business segments
$66.38M totalRx Segment$66.38M · 100.0%
Product / service
$66.38M totalAdhd Portfolio$57.58M · 86.7%
The Pediatric Portfolio$8.77M · 13.2%
Product And Service Other$37.0K · 0.1%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing AYTU BIOPHARMA against the 5 most active filers in the same SIC group.